uracil has been researched along with Acute Confusional Senile Dementia in 11 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we evaluated the efficacy of alogliptin (DPP-4 inhibitor) on hippocampal insulin resistance and associated AD complications." | 7.96 | Alogliptin reversed hippocampal insulin resistance in an amyloid-beta fibrils induced animal model of Alzheimer's disease. ( Akhtar, M; Akhter, M; Kaundal, M; Najmi, AK; Panda, BP; Parvez, S; Rahman, SO; Salman, M; Shrivastava, A, 2020) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| " In this study, we evaluated the efficacy of alogliptin (DPP-4 inhibitor) on hippocampal insulin resistance and associated AD complications." | 3.96 | Alogliptin reversed hippocampal insulin resistance in an amyloid-beta fibrils induced animal model of Alzheimer's disease. ( Akhtar, M; Akhter, M; Kaundal, M; Najmi, AK; Panda, BP; Parvez, S; Rahman, SO; Salman, M; Shrivastava, A, 2020) |
| "Alzheimer's disease (AD) is a senile dementia with increased incidence in older subjects (age >65 years)." | 1.40 | Base excision DNA repair levels in mitochondrial lysates of Alzheimer's disease. ( Bohr, VA; Canugovi, C; Croteau, DL; Shamanna, RA, 2014) |
| "Xanthine levels were increased in the DLB group in the parietal, occipital, and temporal lobes, indicating that peroxynitrite or other deaminating species may be involved." | 1.30 | Oxidative damage to proteins, lipids, and DNA in cortical brain regions from patients with dementia with Lewy bodies. ( Halliwell, B; Ince, PG; Jenner, A; Jenner, P; Lyras, L; Perry, EK; Perry, RH, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Semenov, VE | 5 |
| Zueva, IV | 5 |
| Lushchekina, SV | 5 |
| Suleimanov, EG | 3 |
| Gubaidullina, LM | 4 |
| Shulaeva, MM | 3 |
| Lenina, OA | 4 |
| Petrov, KA | 5 |
| Rahman, SO | 1 |
| Kaundal, M | 1 |
| Salman, M | 1 |
| Shrivastava, A | 1 |
| Parvez, S | 1 |
| Panda, BP | 1 |
| Akhter, M | 1 |
| Akhtar, M | 1 |
| Najmi, AK | 1 |
| Mukhamedyarov, MA | 2 |
| Petukhova, EO | 2 |
| Krylova, ES | 1 |
| Saifina, LF | 2 |
| Zueva, I | 1 |
| Dias, J | 1 |
| Lushchekina, S | 1 |
| Semenov, V | 1 |
| Mukhamedyarov, M | 1 |
| Pashirova, T | 1 |
| Babaev, V | 1 |
| Nachon, F | 1 |
| Petrova, N | 1 |
| Nurullin, L | 1 |
| Zakharova, L | 1 |
| Ilyin, V | 1 |
| Masson, P | 2 |
| Petrov, K | 1 |
| Canugovi, C | 1 |
| Shamanna, RA | 1 |
| Croteau, DL | 1 |
| Bohr, VA | 1 |
| Kharlamova, AD | 1 |
| Mikhailov, AS | 1 |
| Podyachev, SN | 1 |
| Minnekhanova, OA | 1 |
| Zobov, VV | 1 |
| Nikolsky, EE | 1 |
| Reznik, VS | 1 |
| Qin, L | 1 |
| Chong, T | 1 |
| Rodriguez, R | 1 |
| Pugazhenthi, S | 1 |
| Waragai, M | 1 |
| Imafuku, I | 1 |
| Takeuchi, S | 1 |
| Kanazawa, I | 1 |
| Oyama, F | 1 |
| Udagawa, Y | 1 |
| Kawabata, M | 1 |
| Okazawa, H | 1 |
| Lyras, L | 1 |
| Perry, RH | 1 |
| Perry, EK | 1 |
| Ince, PG | 1 |
| Jenner, A | 1 |
| Jenner, P | 1 |
| Halliwell, B | 1 |
| Kruman, II | 1 |
| Kumaravel, TS | 1 |
| Lohani, A | 1 |
| Pedersen, WA | 1 |
| Cutler, RG | 1 |
| Kruman, Y | 1 |
| Haughey, N | 1 |
| Lee, J | 1 |
| Evans, M | 1 |
| Mattson, MP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| High Dose Supplements to Reduce Homocysteine and Slow the Rate of Cognitive Decline in Alzheimer's Disease (Vitamins to Slow Alzheimer's - VITAL)[NCT00056225] | Phase 3 | 340 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for uracil and Acute Confusional Senile Dementia
1 trial available for uracil and Acute Confusional Senile Dementia
10 other studies available for uracil and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Novel Uracil-Based Inhibitors of Acetylcholinesterase with Potency for Treating Memory Impairment in an Animal Model of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Benzoates; Disease Models, Animal; Memory Disorder | 2022 |
Novel Uracil-Based Inhibitors of Acetylcholinesterase with Potency for Treating Memory Impairment in an Animal Model of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Benzoates; Disease Models, Animal; Memory Disorder | 2022 |
Novel Uracil-Based Inhibitors of Acetylcholinesterase with Potency for Treating Memory Impairment in an Animal Model of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Benzoates; Disease Models, Animal; Memory Disorder | 2022 |
Novel Uracil-Based Inhibitors of Acetylcholinesterase with Potency for Treating Memory Impairment in an Animal Model of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Benzoates; Disease Models, Animal; Memory Disorder | 2022 |
Novel Uracil-Based Inhibitors of Acetylcholinesterase with Potency for Treating Memory Impairment in an Animal Model of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Benzoates; Disease Models, Animal; Memory Disorder | 2022 |
Novel Uracil-Based Inhibitors of Acetylcholinesterase with Potency for Treating Memory Impairment in an Animal Model of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Benzoates; Disease Models, Animal; Memory Disorder | 2022 |
Novel Uracil-Based Inhibitors of Acetylcholinesterase with Potency for Treating Memory Impairment in an Animal Model of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Benzoates; Disease Models, Animal; Memory Disorder | 2022 |
Novel Uracil-Based Inhibitors of Acetylcholinesterase with Potency for Treating Memory Impairment in an Animal Model of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Benzoates; Disease Models, Animal; Memory Disorder | 2022 |
Novel Uracil-Based Inhibitors of Acetylcholinesterase with Potency for Treating Memory Impairment in an Animal Model of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Benzoates; Disease Models, Animal; Memory Disorder | 2022 |
Alogliptin reversed hippocampal insulin resistance in an amyloid-beta fibrils induced animal model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Dipeptidyl-Peptidase IV Inhibitors; Dise | 2020 |
Novel Acetylcholinesterase Inhibitors Based on Uracil Moiety for Possible Treatment of Alzheimer Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Ammonium Compounds; Animals; Anions; Behavior, Animal; Bind | 2020 |
New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; CHO Cells; Cholinesterase Inhibitor | 2019 |
Base excision DNA repair levels in mitochondrial lysates of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Dideoxynucleotides; DNA Damage; DNA Ligases; DNA | 2014 |
6-Methyluracil Derivatives as Bifunctional Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Behavior, Animal; Brain; Cholinesterase Inhibitors | 2015 |
Glucagon-Like Peptide-1-Mediated Modulation of Inflammatory Pathways in the Diabetic Brain: Relevance to Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Blood Glucose; Body Weight; Brain; Cytokines; Diabetes Mellitus, Experim | 2016 |
Presenilin 1 binds to amyloid precursor protein directly.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Galactose; Galactosides; Glucose; Hippoc | 1997 |
Oxidative damage to proteins, lipids, and DNA in cortical brain regions from patients with dementia with Lewy bodies.
Topics: Adenine; Aged; Aged, 80 and over; Alzheimer Disease; Brain Chemistry; Cerebral Cortex; Cytosine; DNA | 1998 |
Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Cell Survival; Cells, Cultured; Diet; | 2002 |